Seegene, Inc. (KOSDAQ:096530)
 25,300
 -50 (-0.20%)
  Oct 31, 2025, 3:30 PM KST
Seegene Revenue
Seegene had revenue of 114.06B KRW in the quarter ending June 30, 2025, with 13.90% growth. This brings the company's revenue in the last twelve months to 454.22B, up 18.76% year-over-year. In the year 2024, Seegene had annual revenue of 414.25B with 12.76% growth.
Revenue (ttm) 
 454.22B
Revenue Growth 
 +18.76%
P/S Ratio 
 2.57
Revenue / Employee 
 2.10B
Employees 
 216
Market Cap 
1.17T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 414.25B | 46.88B | 12.76% | 
| Dec 31, 2023 | 367.38B | -486.19B | -56.96% | 
| Dec 31, 2022 | 853.56B | -517.27B | -37.73% | 
| Dec 31, 2021 | 1.37T | 245.62B | 21.83% | 
| Dec 31, 2020 | 1.13T | 1.00T | 822.66% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |